Replies to post #59778 on Biotech Values

[DewDiligence]

Right—RespiGam is the other easy one. The third drug for RSV is the tough one, but it’s a drug that has been much discussed on this board.

[DewDiligence]

AZN gets FDA approvable letter (oops—I mean a Complete Response Letter) for Motavizumab:

http://www.reuters.com/article/marketsNews/idINLS22855520081128

Motavizumab is the next-generation version of the blockbuster Synagis.

When was the last time the FDA granted a full-fledged approval on the first review cycle? I’m seriously having a hard time remembering.